Search Page

1

Cite

Share

Viral Infection and Lung Cancer Immunotherapy.

Kalinka E, Chmielewska I, Wojas-Krawczyk K. Kalinka E, et al. Among authors: chmielewska i. Front Oncol. 2021 Aug 9;11:577514. doi: 10.3389/fonc.2021.577514. eCollection 2021. Front Oncol. 2021. PMID: 34434887 Free PMC article. Review.

Cite

Share

2

Cite

Share

Mechanisms of aromatase inhibitor resistance.

Ma CX, Reinert T, Chmielewska I, Ellis MJ. Ma CX, et al. Among authors: chmielewska i. Nat Rev Cancer. 2015 May;15(5):261-75. doi: 10.1038/nrc3920. Nat Rev Cancer. 2015. PMID: 25907219 Review.

Cite

Share

3

Cite

Share

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer-Clinical Trials Experience.

Chmielewska I, Stencel K, Kalinka E, Ramlau R, Krawczyk P. Chmielewska I, et al. Cancers (Basel). 2021 Oct 9;13(20):5048. doi: 10.3390/cancers13205048. Cancers (Basel). 2021. PMID: 34680195 Free PMC article. Review.

Cite

Share

4

Cite

Share

Not only cigarettes - other culprits of lung cancer.

Grzywa-Celińska A, Drogoń I, Emeryk-Maksymiuk J, Chmielewska I, Milanowski J. Grzywa-Celińska A, et al. Among authors: chmielewska i. Ann Agric Environ Med. 2019 Dec 19;26(4):661-664. doi: 10.26444/aaem/109688. Epub 2019 Jun 14. Ann Agric Environ Med. 2019. PMID: 31885242 Free article.

Cite

Share

5

Cite

Share

Non-Small-Cell Lung Cancer: New Rare Targets-New Targeted Therapies-State of The Art and Future Directions.

Stencel K, Chmielewska I, Milanowski J, Ramlau R. Stencel K, et al. Among authors: chmielewska i. Cancers (Basel). 2021 Apr 12;13(8):1829. doi: 10.3390/cancers13081829. Cancers (Basel). 2021. PMID: 33921237 Free PMC article. Review.

Cite

Share

6

Cite

Share

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.

Krawczyk P, Grenda A, Terlecka P, Błach J, Wojas-Krawczyk K, Kucharczyk T, Chmielewska I, Kieszko R, Jarosz B, Gil M, Reszka K, Milanowski J. Krawczyk P, et al. Among authors: chmielewska i. Sci Rep. 2021 Oct 22;11(1):20939. doi: 10.1038/s41598-021-00309-3. Sci Rep. 2021. PMID: 34686712 Free PMC article.

Cite

Share

7

Cite

Share

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review.

Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Dudzińska M, et al. Among authors: chmielewska i. Cancers (Basel). 2020 Aug 17;12(8):2314. doi: 10.3390/cancers12082314. Cancers (Basel). 2020. PMID: 32824462 Free PMC article. Review.

Cite

Share

8

Cite

Share

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients.

Grenda A, Krawczyk P, Błach J, Chmielewska I, Kubiatowski T, Kieszko S, Wojas-Krawczyk K, Kucharczyk T, Jarosz B, Paśnik I, Borowiec-Bar M, Frąk M, Kieszko R, Szczyrek M, Reszka K, Krukowska K, Kolak A, Mańdziuk S, Kowalski D, Sawicki M, Świniuch D, Starosławska E, Ramlau R, Szumiło J, Krzakowski M, Milanowski J. Grenda A, et al. Among authors: chmielewska i. Front Oncol. 2021 Feb 8;10:563613. doi: 10.3389/fonc.2020.563613. eCollection 2020. Front Oncol. 2021. PMID: 33628725 Free PMC article.

Cite

Share

9

Cite

Share

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient.

Krukowska K, Kieszko R, Kurek K, Chmielewska I, Krawczyk P, Milanowski J. Krukowska K, et al. Among authors: chmielewska i. Case Rep Oncol Med. 2020 May 8;2020:4196178. doi: 10.1155/2020/4196178. eCollection 2020. Case Rep Oncol Med. 2020. PMID: 32455036 Free PMC article.

Cite

Share

10

Cite

Share

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?

Chmielewska I, Dudzińska M, Szczyrek M, Świrska J, Wojas-Krawczyk K, Zwolak A. Chmielewska I, et al. PLoS One. 2021 Sep 29;16(9):e0257484. doi: 10.1371/journal.pone.0257484. eCollection 2021. PLoS One. 2021. PMID: 34587185 Free PMC article.

Cite

Share